{"nctId":"NCT00242567","briefTitle":"Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer","startDateStruct":{"date":"2005-12"},"conditions":["Prostate Cancer"],"count":522,"armGroups":[{"label":"Early Group","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic Acid"]},{"label":"Delayed group","type":"EXPERIMENTAL","interventionNames":["Drug: Androgen Deprivation Therapy (ADT)"]}],"interventions":[{"name":"Zoledronic Acid","otherNames":[]},{"name":"Androgen Deprivation Therapy (ADT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* prostate cancer\n* at least one bone metastasis\n* receiving or about to receive androgen deprivation therapy (ADT)\n\nExclusion Criteria:\n\n* previous ADT failure\n* previous or current treatment with another bone-protecting agent, chemotherapy or targeted therapy\n* abnormal renal function\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Skeletal-related Event-free Survival in Men With Bone Metastases From Prostate Cancer","description":"Skeletal-related event free survival is the time from randomization until the first detected Skeletal Related Event (SRE). Patients who were still SRE-free at 18 months were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"201","spread":null},{"groupId":"OG001","value":"214","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival at 18 Months and 3 Years","description":"Overall survival (OS) time was measured from the start of study drug to the date of death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"228","spread":null},{"groupId":"OG001","value":"242","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"219","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Occurrence of Skeletal Related Event or Death","description":"Time from randomization to the first detected skeletal related event or death. This endpoint is the same as the primary endpoint with the modification that deaths are considered events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Skeletal-related Event(SRE)-Free Survival","description":"Time from randomization until the first detected SRE. Patients who were still SRE-free at 3 years were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Occurrence of Skeletal Related Event or Death","description":"Time from randomization to the first detected skeletal related event or death. This endpoint is the same as the primary endpoint with the modification that deaths are considered events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":121,"n":259},"commonTop":["PROSTATIC SPECIFIC ANTIGEN INCREASED","BACK PAIN","CONSTIPATION","ARTHRALGIA","PAIN IN EXTREMITY"]}}}